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CopyrigABSTRACT: Quantitative structure–activity relationship (QSAR) studies and mechanistic mathe-
matical modeling approaches have been independently employed for analysing and predicting the
transport and distribution of small molecule chemical agents in living organisms. Both of these com-
putational approaches have been useful for interpreting experiments measuring the transport prop-
erties of small molecule chemical agents, in vitro and in vivo. Nevertheless, mechanistic cell-based
pharmacokinetic models have been especially useful to guide the design of experiments probing
the molecular pathways underlying small molecule transport phenomena. Unlike QSAR models,
mechanistic models can be integrated from microscopic to macroscopic levels, to analyse the spatio-
temporal dynamics of small molecule chemical agents from intracellular organelles to whole organs,
well beyond the experiments and training data sets upon which the models are based. Based on dif-
ferential equations, mechanistic models can also be integrated with other differential equations-based
systems biology models of biochemical networks or signaling pathways. Although the origin and
evolution of mathematical modeling approaches aimed at predicting drug transport and distribution
has occurred independently from systems biology, we propose that the incorporation of mechanistic
cell-based computational models of drug transport and distribution into a systems biology modeling
framework is a logical next step for the advancement of systems pharmacology research. Copyright
© 2013 John Wiley & Sons, Ltd.
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Cell-based computational modeling of drug trans-
port and distribution is an active area of research
in pharmaceutical sciences, because the subcellu-
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ht © 2013 John Wiley & Sons, Ltd.dimensional architecture of cells, tissues and or-
gans ultimately deﬁnes the site of action of drug
molecules in the body. In multicellular organisms,
cell monolayers constitute physical boundaries
that separate one tissue or anatomical compart-
ment from another, and determine the movement
of molecules between compartments. For exam-
ple, in the gastrointestinal tract, the monolayer of
epithelial cells that lines the lumen of the gut also
controls the absorption of nutrients and xenobi-
otics into the body (Figure 1A). After absorption,
nutrients and xenobiotics also have to make theirReceived 29 June 2013
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Figure 1. Cellular pharmacokinetic models can be used to study the transport and distribution of small molecules in the presence of
a transcellular concentration gradient. As drugs are absorbed across the lining of the gastrointestinal tract (A) or as they are metab-
olized in the hepatocytes (B), cells normally experience a transcellular drug concentration gradient. Outside the cells, drug mole-
cules can exist in free or bound forms. Only freely soluble molecules can diffuse across the membranes. Inside the cells, drug
molecules can be metabolized, partition into cellular lipids, bind to cellular macromolecules, or become sequestered in organelles.
All these mechanisms are inﬂuenced by chemical parameters such as the lipophilicity (as reﬂected in the octanol:water partition
coefﬁcient); the ionization states of the molecules (pKa); physiological parameters such as the pH of the different compartments
and the electrical potentials across their bound membranes; and, biological parameters such as the volume and number of organ-
elles, member surface areas and the presence of binding, sorption and active transport mechanisms, as well as chemical transfor-
mations (Km and Vmax) catalysed by metabolic enzymes
16 K.A. MIN ET AL.way through hepatocytes in the liver where
specialized efﬂux mechanisms and metabolizing
enzymes act to keep xenobiotics from reaching
the systemic circulation [1] (Figure 1B). Therefore,Copyright © 2013 John Wiley & Sons, Ltd.the ability to model, analyse and predict the
subcellular transport properties of drug-like mole-
cules is an increasingly important area of research
in pharmaceutical sciences. Similarly, to the extentBiopharm. Drug Dispos. 35: 15–32 (2014)
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and predict the spatiotemporal dynamics of the ef-
fects of drugs on living systems, modeling the
transport and distribution phenomena affecting
the concentrations of drug molecules in different
sites of an organism may be as important as
modeling the effects of drug molecules on bio-
chemical reactions, signal transduction pathways
or other regulatory molecular control networks
that are currently the subject of systems biology
research.
At the level of the whole organism, the develop-
ment and application of computational models to
predict drug transport phenomena has been an ac-
tive area of pharmacokinetics research for many
years. For example, physiologically based phar-
macokinetic (PBPK) models are mechanism-based
mathematical models that have been used to ana-
lyse the concentration and distribution of drugs
from the circulation to the different organs, based
on the perfusion and permeability characteristics
of each organ. In drug development, PBPK
models allow the prediction of drug distribution
from one species of organism to another [2–4].
Since their origin in the 1970s, a variety of PBPK
modeling approaches have been developed to
analyse the spatiotemporal dynamics of a wide
range of drug absorption, distribution, metabo-
lism and elimination phenomena affecting drug
activity and toxicity [5–13]. Nevertheless, local
concentrations of drug molecules at the micro-
scopic sites where drug molecules interact with
their intended (or unintended) biological targets
may not be necessarily the same as the concentra-
tions of drug molecules in macroscopic bulk com-
partments. This is because cells and subcellular
organelles are delimited by membranes, and drug
transport across these membranes is determined
by active and passive transport mechanisms that
can facilitate the accumulation of drug molecules
on one side of the membrane relative to the other.
Beyond PBPK modeling, molecular mechanisms
affecting the active transport of drugs into subcel-
lular compartments could be the subject of sys-
tems pharmacology research. These mechanisms
include protein ‘pumps’ that translocate drug
molecules from one side of the plasma membrane
to the other by using energy derived from ATP
hydrolysis. In addition, the passive distribution
of drugs across plasma and organelle membranesCopyright © 2013 John Wiley & Sons, Ltd.can be inﬂuenced by differences in the local micro-
environment of the two compartments separated
by membranes. These differences lead to trans-
membrane pH gradients and electrical potentials
affecting the transport and distribution of mole-
cules possessing charged or ionizable functional
groups. From the perspective of systems pharma-
cology, microscopic transmembrane transport
phenomena can be considered as the key determi-
nants of whether or not small molecule chemical
agents can interact with the molecular circuitry
that establishes and controls the structure and
function of the organism. If the site of the action
of a drug molecule is located in a speciﬁc organ-
elle inside a speciﬁc cell type, the rate and extent
to which the drug may accumulate at that target
site can be inﬂuenced by active and passive trans-
port mechanisms that may facilitate or prevent a
drug from reaching that site. Similarly, if the drug
target is localized on an extracellular membrane
surface, mechanisms that drive the sequestration
of drug molecules inside cells or that facilitate
their excretion from the organism can effectively
reduce extracellular drug concentrations to the
point where the drug may be unable to inﬂuence
the function of an extracellular target [14–19].
Nevertheless, at this microscopic level, pharma-
ceutical researchers have also been elaborating
computational models to predict the transcellular
permeability of small molecule chemical agents
and to develop small molecule chemical agents
targeted to speciﬁc sites of action inside cells
[5,7,8,20–23]. In general, there have been two
kinds of mathematical approaches applied
towards predicting the subcellular transport and
distribution properties of small drug-like mole-
cules: statistics-based QSAR studies and differen-
tial equations-based mechanistic modeling.
QSAR involves the application of correlation
analyses to determine associations between the
chemical structures and the subcellular transport
and distribution properties of small molecules
[8,21–28]. Mechanistic modeling involves using
differential equations to represent the transport
of molecules as a change in the concentration of
molecules between compartments separated by
cellular membranes [5,7,8]. The following sections
discuss how these two different computational
approaches originated and evolved, and evaluate
their potential impact on the ﬁeld of systemsBiopharm. Drug Dispos. 35: 15–32 (2014)
DOI: 10.1002/bdd
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of relevant research studies analysing drug–drug
interactions and the interplay between efﬂux
transporters, metabolic enzymes and drug targets
while integrating pharmacokinetics and pharma-
codynamics at cellular and subcellular levels.QSAR Studies of Drug Transport and
Distribution in Single Cells
The QSAR approach to predictive cellular phar-
macokinetics can be considered an extension of
classical QSAR studies which have been used
widely in pharmaceutical and medicinal chemis-
try research since the 1960s [29]. For classical
QSAR studies, multivariate, statistical regression
techniques are used to link the results of experi-
mental assays to the chemical structures of large
sets of chemical agents tested with these assays.
The regression techniques yield an equation that
speciﬁes the relationship between a physicochem-
ical or biological property of interest (the depen-
dent variable of the equation) to different input
parameters that represent the chemical structures,
atomic composition or physicochemical properties
of the assayed molecules (the independent vari-
ables of the equation). Using a training set of
molecules, the resulting regression equations can
be used to predict the behavior of untested sets
of molecules using the molecule’s chemical struc-
ture or physicochemical properties as input [29].
Examples of QSAR studies range from the predic-
tion of in vitro solubility [30–34] to the predictionTable 1. Examples of empirical QSAR models for predicting subce
Method Localization D
QSAR Mitochondria lo
QSAR Lysosome lo
QSAR Nuclei lo
L
QSAR ER lo
QSAR Mitochondria/non-mitochondria lo
MLR (multiple
linear regression)
Mitochondria lo
Descriptor Mitochondria/lysosome/nuclei/cytosol/
ER/Golgi body/plasma membrane/
multiple localization
4
logP, logarithm of the octanol/water partition coefﬁcient; logD, logarithm
logarithm of the acidic associate constant; Z, electrical charge; CBN, conjug
fragment; α, polarizability; MW, molecular weight; PSA, polar surface area.
Copyright © 2013 John Wiley & Sons, Ltd.of complex biological properties, such as in vivo
bioavailability [35–37].
While several other different QSAR approaches
have been developed to link the chemical struc-
ture with the physicochemical properties or phar-
macological activities of small molecules [38–47],
there are fewer examples of QSAR approaches
linking the structure of small molecules with their
cellular transport and distribution properties
(Table 1) [8,25–27,48–50]. Interestingly, some of
the ﬁrst QSAR models ever published were aimed
at predicting drug concentrations in cells. These
QSAR models date all the way back to the 1960s.
Indeed some of the original QSAR models were
elaborated to describe the relationship between
hydrophobicity and the biological activity of
chemical agents, related to the ability of lipophilic
molecules to cross cellular membranes but with-
out partitioning into those membranes [29,51,52].
Subsequently, these regression-based QSAR
models were elaborated and applied in an increas-
ingly sophisticated manner, to study drug disposi-
tion and activity in multicompartment (aqueous
and lipid) biosystems [28,53,54] and to analyse
concentration–time proﬁles in bacterial or mam-
malian cells [55–59].
To predict the distribution of small molecules in
different organelles of eukaryotic cells, a different
kind of QSAR modeling approach was introduced
in the 1990s, based on the construction of nested
if/then rules [60]. With this approach, a simple
decision tree-like model, named the Chinese box
model, was used to describe the distribution of
small drug-like molecules inside cells [27,48].llular distribution
escriptors Number of compounds References
gP, Z 41
gP, pKa, CBN, Z 50 [27]
gP, pKa, Z, CBN, AI, LCF,
CF/CBN ratio
44 [25]
gP, pKa, Z, CBN, AI, LCF 37 [26]
gP, pKa, Z, CBN, AI, LCF 109 [60]
gD, Z, α, MW, PSA 20 [50]
83 2D and 3D descriptors 967 [66]
of the octanol/water partition coefﬁcient at pH 7.4; pKa, negative
ated bond number; AI, amphilicity index; LCF, the largest conjugated
Biopharm. Drug Dispos. 35: 15–32 (2014)
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probes to study their mitochondrial localization
as a function of the logarithm of the octanol/water
partition coefﬁcient (logP) [48]. Based on this
model, cationic molecules with logP between
0 and 5 were expected to accumulate in the mito-
chondrial inner membrane. Cationic molecules
with a logP< 0 would be excluded outside cells,
and with a logP>+5 would accumulate preferen-
tially in the plasma membrane [48]. A few years
later, a similar decision tree-like model was built
to analyse the accumulation of small molecules
in lysosomes [27]. Based on this model, probes
were classiﬁed into three major categories: (1)
those that had 0< logP< 5 were able to cross the
plasma membrane; (2) those that had logP> 15
could also enter the cell and accumulate in lyso-
somes by adsorptive pinocytosis; and (3) those
that had logP< 0, z< 0 could also enter cells and
accumulate in lysosomes by ﬂuid phase pinocyto-
sis. Probes in group (1) were classiﬁed into two
sub-categories: (1) Probes accumulating in lyso-
somes by ion trapping mechanisms; and, (2)
probes comprising hydrolysable lipophilic esters,
usually weak acids, which were metabolized into
free acids by lysosomal esterases and trapped in
lysosomes by precipitation in the low pHmicroen-
vironment [27]. To further extend this decision-
tree based approach, additional studies with
molecules localizing to other organelles (endoplas-
mic reticulum, nuclear chromatin and plasma
membrane) have been performed [26,60,61].
More recently, an additive factorial logistic
regression modeling approach was developed to
analyse the subcellular localization of a combina-
torial library of organelle-targeting cationic styryl
dyes [21,62]. Each styryl dye was synthesized
using a chemical conjugation reaction to link two
chemical building blocks: an aldehyde building
block combined with a pyridinium or quinolinium
building block. By combining 168 aldehyde with
eight pyridinium or quinolinium building blocks,
the contributions of each building block to the
peak excitation and emission wavelength of
1344 molecules in the library was calculated using
least squares to minimize an additive, multivari-
ate regression function over all compounds hav-
ing experimental data [21,62]. Most importantly,
using a factorial logistic regression approach, the
binary (mitochondrial vs nonmitochondrial)Copyright © 2013 John Wiley & Sons, Ltd.localization data obtained from live cells incu-
bated with these compounds were also related
to the quantitative contributions of each aldehyde
and pyridinium or quinolinium building blocks.
Cross-validation was carried out for both spectral
and localization data, to obtain unbiased esti-
mates of prediction performance.
While most QSAR studies have focused on
analysing the steady state distribution of small
molecule chemical agents inside cells (for recent
reviews, see [63–65]), complementary QSAR ap-
proaches have been developed to study the cellu-
lar and subcellular transport kinetics of small
molecules. In one study, the time of exposure
was integrated with a QSAR model to capture
the kinetics of the drug–receptor interaction based
on the law of mass action [28]. This ‘QSTAR’
model was developed by applying non-linear
regression to a data set of 36 compounds [28]. Sub-
sequently, this QSTAR modeling approach was
further elaborated by incorporating enzymatic
activity, membrane accumulation, non-covalent
protein binding and excretion [56]. In a different
study, using a combinatorial library of ﬂuores-
cently tagged cell-permeant small molecule chem-
ical agents, a nested multi-compartment model
was used to analyse the subcellular transport
and accumulation kinetics of the compounds be-
tween extracellular medium, cytosol and intracel-
lular vesicles [22]. Using kinetic image data
acquired from cells incubated with the ﬂuorescent
compounds at different times after the probes
were added to the cells, changes in the total inten-
sity and coefﬁcients of variation of pixel intensi-
ties were linked to changes in the intracellular
concentration of the probes. Using this approach,
the partition coefﬁcients from the extracellular
medium to the cytosol, and from the cytosol to
the intracellular vesicles was inferred and related
to the chemical structures of the compounds [22].
Most recently, a database of 967 molecules with
published subcellular localization features de-
rived from a survey of the scientiﬁc literature
was used as a starting point for identifying rela-
tionships between the chemical space occupied
by small molecules and their reported intracellu-
lar localization features [66]. Because this is a
diverse group of compounds whose localization
was determined by a large number of different
investigators using a wide variety of differentBiopharm. Drug Dispos. 35: 15–32 (2014)
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structure–localization relationship study was not
performed. Nevertheless, by studying the locali-
zation of compounds to multiple different organ-
elles, this study identiﬁed many interesting,
candidate chemical property–subcellular localiza-
tion relationships that had not been noted previ-
ously in QSAR studies focusing on a single
target organelle. Amongst the most interesting
trends, the molecular weight of the compounds
was identiﬁed as a key variable associated with
differences in the subcellular distribution proper-
ties of small molecules. More speciﬁcally, the
chemical property–subcellular localization rela-
tionships of the compounds was very different
for molecules> 500 Daltons compared with those
that were< 500 Daltons.Mechanistic Models of Drug Transport and
Distribution in Single Cells
The development of mechanistic models of drug
transport and distribution at the single cell level
began in the 1970s, with the incorporation of per-
meability as a parameter variable in the physio-
logically based pharmacokinetic (PBPK) model.
In these models, permeability was used to capture
differences in the rate of accumulation of drug
molecules in the different organs. However, it
was not until the mid-1990s that attempts were
made to relate the abstract, pharmacokinetic per-
meability parameter to the physical cell perme-
ability. The realization of the importance of cell
permeability in pharmaceutical discovery was
spurred by the development of the advanced com-
partmental absorption and transit model (ACAT)
[67]. The development of the ACAT model effec-
tively connected the results of in vitro cell-based
assays measuring the transport rates of small mol-
ecule drugs across cell monolayers to the fraction
of an oral dose of drug absorbed in the gastroin-
testinal tract.
To analyse the results of in vitro cell-based
transport assays, compartmental cellular phar-
macokinetic models began to be constructed to
analyse cellular transport and metabolism prop-
erties of small molecules across cell monolayers,
in the presence of a transcellular concentration
gradient [6–8,11,54,68]. By incorporating theCopyright © 2013 John Wiley & Sons, Ltd.Goldman–Hodgkin–Katz equation, differential
equation-based cellular pharmacokinetic models
have been converted into predictive cell-based
transport and distribution models. The Goldman-
Hodgkin-Katz equation is derived from the
Nernst–Planck equation (Equation (1)).
J ¼ D dC xð Þ
dx
þ C xð Þ zF
RT
dV xð Þ
dx
 
(1)
The ﬁrst term corresponds to the ﬂux of the
neutral species captured by Fick’s law of diffu-
sion. The second term corresponds to the ﬂux of
the ionized species which is inﬂuenced by the
transmembrane electrical potential. D is the diffu-
sion coefﬁcient (area per time unit). F, R, T and z
are the Faraday’s constant, molar gas constant,
temperature (in Kelvin) and electric charge,
respectively. Assuming the transport direction
(denoted by x) being perpendicular to the mem-
brane, then dC(x)/dx reﬂects the concentration
change along the membrane, and dV(x)/dx
reﬂects the voltage change along the membrane.
C(x) indicates the concentration at point x. If the
transmembrane electrical potential is assumed to
be constant along the membrane, and the mem-
brane thickness is d, Equation (1) is rewritten as
Equation (2).
J ¼ D dC xð Þ
dx
þ C xð Þ zF
RT
V
d
 
(2)
Rearranging the terms in Equation (2) leads to
Equation (3):
1 ¼ dC xð Þ=dx JD C xð Þ zFRT Vd
(3)
Letting N=zFV/RT, and integrating from x = 0
to d yields Equation (4):
∫d0 dx ¼ ∫
d
0 
dC xð Þ=dx
J=DþNC xð Þ=d dx
d ¼  d
N
ln
N
d
C dð Þ þ J
D

 ln Nd C 0ð Þ þ
J
D


 
(4)
Accordingly, the ﬂux of a charged molecule
across a biomembrane with a transmembraneBiopharm. Drug Dispos. 35: 15–32 (2014)
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captured by Equation (5):
J ¼ D
d
N
eN  1 C 0ð Þ  e
NC dð Þ  (5)
where D/d captures the permeability of the mole-
cule across the membrane (length per time units).
C(0) is the concentration at the outer membrane
surface, and C(d) is the concentration at the inner
membrane surface.
To facilitate predictions, the ﬂux of a molecule
across a membrane can be expressed with Fick’s
equation (Equation (6)).
Jn ¼ Pn Co;n  Ci;n
 
(6)
where Pn is the membrane permeability which can
be estimated as a function of the octanol:water
partition coefﬁcient of the neutral form of the
molecule, Cn is the concentration of neutral form
of the molecule with the subscripts o and i indicat-
ing the directions of the ﬂux, J, from outside to
inside compartments. Similarly, for charged mole-
cules, the net ﬂuxes of passive diffusion across
membranes can be expressed using Pd as the
membrane permeability of the ionized form of
the molecule which can also be estimated as a
function of the octanol:water partition coefﬁcient,
with Equation (7) (derived from Equation (5))
Jd ¼ Pd
N
eN  1 Co;d  Ci;de
N  (7)
For Equation (7), subscript d indicates the ionized
form of the molecule. Co,d and Ci,d are the concen-
tration of ionized forms of the molecule outside
and inside, respectively. Combining Equations (6)
and (7) (Fick’s and Goldman–Hodkin–Katz equa-
tion) and considering as the thermodynamic activ-
ity (a) of the different protonated states of a
molecule may differ from their concentration
depending on the pH, ionic strength, and binding
to macromolecules and lipids present in the local
microenvironment, the net ﬂuxes of molecule
weakly basic or weakly acidic molecule acrossCopyright © 2013 John Wiley & Sons, Ltd.lipid membranes delimiting cells and the various
intracellular organelles can be described with
Equation (8).
J ¼ Pn ao;n  ai;n
 þ Pd NeN  1 ao;d  ai;deN
 
(8)
This equation directly captures the transmem-
brane ﬂuxes of neutral and ionized species of
monovalent weak acids and bases and can be
elaborated further to capture dibasic, diacidic
and zwitterionic small molecules [5,66,69]. For
simulating subcellular transport phenomena with
this equation, input parameters can be systemati-
cally varied, to capture the behavior of molecules
with varying physicochemical properties, as well
as to study the effect of variations in cell morphol-
ogy and physiology on cellular pharmacokinetics.
This equation has been parameterized to simulate
the subcellular transport and disposition proper-
ties of small molecules in single cells suspended
in a homogeneous extracellular drug concentration
(Figure 2A) as well as in attached cell monolayers
surrounded by a transcellular concentration gradi-
ent (Figure 2B) [5,7,8,69,70].Role of Mechanistic Cellular Pharmacoki-
netic Modeling in Pharmacology
From an empirical pharmacological perspective,
cellular pharmacokinetic models have been
mostly used to analyse the interaction of small
molecule chemical agents with speciﬁc intracellu-
lar drug targets, in the context of passive and ac-
tive transport mechanisms affecting the transport
of the molecules between extracellular and intra-
cellular compartments (Table 2). One excellent
example of such an application involved studying
the effect of P-glycoprotein (P-gp) on the intracel-
lular binding of paclitaxel to microtubules
[20,71,72]. The model took into account saturable
binding to extracellular proteins, saturable and
nonsaturable binding to intracellular components,
cell density variation and changes in tubulin con-
centration as a function of paclitaxel concentra-
tion. First, the model was validated in human
breast MCF7 tumor cells, which had negligible P-
glycoprotein expression, after which the effect of
P-glycoprotein mediated efﬂux was added intoBiopharm. Drug Dispos. 35: 15–32 (2014)
DOI: 10.1002/bdd
Figure 2. Passive transport mechanisms can be modeled to predict the accumulation and distribution of the weakly basic small mol-
ecule inside cells surrounded by a homogeneous drug concentration (A) or in the presence of a transcellular concentration gradient
(B). For mechanistic modeling, the different ionization states of the molecule is calculated using the Henderson-Hasselbalch equa-
tion (1). Transport of the neutral or charged (ionized) species of the molecule from the surrounding medium or the apical compart-
ment into the cells (2) can be modeled with the Fick and Goldman–Hodgkin–Katz equations. From the cytosol, transport into
lysosomes (3) or mitochondria (4), as well as transport from the cytosol into the basolateral compartment can also be modeled with
the Goldman–Hodgkin–Katz equation
Table 2. Examples of mechanistic cellular pharmacokinetic models
Drugs/molecules Model components Cell type
Relation to systemic
PK/PD References
Monovalent
small molecules
Passive transcellular transport and
subcellular organelles
Epithelial and round shaped
non-polarized cells
Absorption, tissue
distribution
[5,7,8,69]
Paclitaxel P-gp efﬂux, extracellular/
intracellular binding
Human breast cancer cell
lines MCF7 and BC19
Uptake to
cancer cells
[20,71,72]
Substrates of
multiple
transporters
Active uptake, passive diffusion,
nonspeciﬁc binding
Chinese hamster ovary (CHO)
cells overexpressing OATP1A1
or OATP1B1 and
rat hepatocytes
Liver clearance [74]
Ranitidine Uptake and efﬂux transporters,
paracellular and transcellular
transport
Caco-2 Absorption [75]
Baicalein Passive diffusion, cellular binding,
transporters and enzymes
Caco-2 or other similar
in vitro system
Absorption,
metabolism
[6]
GCSF Endosomal trafﬁcking, PK/PD GCSF-dependent human
suspension cell line:
OCI/AML1
Cell-mediated
clearance, link
with PD modeling
[138]
22 K.A. MIN ET AL.the model and validated in a human breast carci-
noma cell line derived from MCF7 cells
transfected with mdr1 [72]. As a follow-up study,
a parametric analysis was performed to study
the differential effects of the extracellular drugCopyright © 2013 John Wiley & Sons, Ltd.concentration, intracellular drug binding capacity
and afﬁnity, and P-glycoprotein expression level
on the intracellular drug accumulation [20]. The
study showed that the four biological factors
determined paclitaxel intracellular concentrationBiopharm. Drug Dispos. 35: 15–32 (2014)
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extracellular concentration was the most sensitive
factor, followed by intracellular binding capacity
and afﬁnity. The effect of P-glycoprotein expression
was relatively minor, suggesting that to improve
clinical efﬁcacy, effective delivery of paclitaxel to
tumor cells was more important than other factors,
such as inhibition of P-glycoprotein efﬂux.
Another important application of empirical,
mechanistic cellular pharmacokinetic modeling
involved the determination of Vmax and Km values
of drug transporters and enzymes with an intra-
cellular site of action, using the results of experi-
ments performed with intact cells [72–75]. Based
on extracellular drug concentrations, the mecha-
nism-based empirical modeling approach can
facilitate an estimation of intracellular Vmax and
Km values, or elementary rate constants of en-
zymes including drug transporters in their natu-
ral, intracellular microenvironments [76–78].
Using a mechanistic cell-based transport and dis-
tribution model to guide interpretation of experi-
mental measurements, parameters associated
with the effect of an enzyme substrate or inhibitor
can be estimated by ﬁtting the experimental data
with a model, using nonlinear least-squares
regression. For modeling drug metabolism, a cate-
nary model based on the compartmental analysis
was developed to analyse the activity of intracel-
lular, drug metabolizing enzymes [6]. This model
captured the mechanisms of passive diffusion,
cellular binding, carrier-mediated and efﬂux
transporter-mediated transport, in addition to
metabolic activity. The model was applied to
study the transport and metabolism of baicalein
inside cells [6]. This empirical, compartmental
modeling approach has also been applied to facil-
itate the design and interpretation of experiments
exploring the role of transporters and metabolic
enzymes in limiting drug absorption and has
helped to explore the molecular mechanisms
responsible for drug–drug interactions [11,79–84].
Empirical, compartmental, cellular pharmacoki-
netic modeling approaches are increasingly being
used to help to interpret the interplay between
drug molecules, drug transporters and metabolic
enzymes, from a molecular, mechanistic perspec-
tive [85–87].
Arguably, for the future development of systems
pharmacology, the application of differentialCopyright © 2013 John Wiley & Sons, Ltd.equations-based,mechanistic mathematical models
will become increasingly important, because many
biochemical and signaling networks are localized
at speciﬁc organelles inside the cell. For example,
mitochondria are involved in the regulation of apo-
ptosis, and thus are considered as important target
sites for anticancer agents [88–90]. Mitochondria
are also the sites of energy production, with the
electron transport chain located in the mitochon-
drial inner membrane generating a marked electri-
cal potential and pH gradient [91,92]. Many
lipophilic cations have been observed accumulating
in mitochondria as a function of the transmem-
brane electrical potential, which can be predicted
with a compartmental, cellular pharmacokinetic
model using the Goldman–Hodgkin–Katz equa-
tion [21,91,93–95]. Examples of these molecules in-
clude rhodamine 123 [91,93,96,97], F16 [88,89] and
styryl molecules [98–101]. Differences in mitochon-
drial membrane potential and pH gradient explain
differences in the toxicity of cationic compounds
on different cell lines of different origins [91].
Like mitochondria, lysosomes are another ex-
ample of an organelle that is interesting from a
systems pharmacology perspective. Biologically,
mutations in genes affecting lysosomal function
lead to a range of protein and membrane accumu-
lation defects that are characteristics of lysosomal
storage diseases [102]. Unlike mitochondria, the
intralumenal pH of lysosomes is acidic [103] while
the cytosolic pH is near neutrality [18]. The low
pH of lysosomes is caused by the activity of a pro-
ton ATPase [103]. As a result, weakly basic mole-
cules tend to accumulate inside lysosomes by a
pH-dependent ion-trapping mechanism [104]: for
weakly basic molecules with a pKa close to physi-
ological pH, they exist predominantly as neutral
species in cytosol (pH~7.2). After neutral mole-
cules enter the acidic subcellular organelles, they
become protonated due to the acidic environment.
Generally, the lipophilicity may differ greatly be-
tween neutral species and ionized species [8].
Therefore, after entering the acidic compartment,
the transmembrane permeability of the molecules
is reduced due to the protonation, and accumula-
tion is induced. Because of the ion-trapping mech-
anism, many clinically useful drugs accumulate in
lysosomes, including the antimalarial drug chlo-
roquine [105,106], as well as many antidepressant
drugs [107].Biopharm. Drug Dispos. 35: 15–32 (2014)
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macokinetic models have been useful to describe
organelle targeting, drug bioaccumulation inside
cells, and also to predict the effect of microenviron-
ments on drug transport and distribution inside
cells [5,7,8,69,70], these models can also be used
as building blocks to study drug transport in
higher order cellular organizations, from the tissue
to the organ level [108,109]. The ability to model
the transport properties of small molecules at the
level of single cells, and to predict the pharmacoki-
netics and biodistribution properties of drug from
organelles to cells to tissues to organisms could
be used to predict systemic pharmacokineticFigure 3. Mechanistic modeling facilitates predicting the transport
scopic to the macroscopic level. At the macroscopic level (A) the a
comprise cylinders. Histologically, the walls of these cylinders can
grating the transport of small molecules across these multilayered o
centrations over time at both local and systemic levels. (B) Using
cellular labeling patterns of the probes can be related to prediction
distribution of Mitotracker Red (red), Hoechst 33342 (blue) and Rho
ministered directly into the airways. Relative to the other two ﬂuore
cells that line the airways, as predicted by its transmembrane trans
periments and build models. The models are used to make predictio
to formulation of new hypotheses leading to further development
Copyright © 2013 John Wiley & Sons, Ltd.parameters, such as the volume of distribution. In-
deed, correlative in vitro and in vivo studies suggest
that the volume of distribution and the intracellu-
lar accumulation of small molecules are related to
each other [110–114]: propranolol, a drug with a
high volume of distribution, mostly accumulates
in association with mitochondria [110]. Meﬂo-
quine, another drug with a very large volume of
distribution, extensively accumulates in lysosomes
[114]. Other basic drugs with large volumes of
distribution that accumulate in lysosomes are
chlorpromazine, imipramine and biperiden
[111,112,115]. Extensive distribution in the lung
has been observed for many lipophilic basesand distribution properties of small molecules from the micro-
natomy of an organ can be modeled geometrically as surfaces
be modeled as concentric layers of different cell types. By inte-
rganizations, it is possible to calculate the changes in drug con-
ﬂuorescent molecules as probes of transport phenomena, the
s based on the models. In this case, the micrograph shows the
damine 1,2,3 (green) in the lungs, after the dyes have been ad-
scent probes, Mitotracker Red was retained inside the epithelial
port properties. Hypotheses are used to guide the design of ex-
ns which may or may not be validated by experiments, leading
of the models
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proposed as a mechanism contributing to high
drug accumulation in the lung [113,115,119,120].
Interestingly, lysosomal volume changes have been
independently implicated in various drug–drug
interactions involving lysosomotropic compounds
[121,122].
Illustrating the application of mechanistic cellu-
lar pharmacokinetic models for predicting small
molecule transport and distribution from theFigure 4. Transmembrane mass transport equations can be used
multicellular organizations. The same equations can be used
membrane-bound organelles, as can be used to capture the transpor
that diffuses from one side of the membrane to the other over tim
membrane (J) times the area of the membrane (A). For passively d
ization states of the molecules, the transcellular concentration gra
permeability of each ionized or neutral molecular species. Membran
that reﬂect the overall number, volume, shape, spatial arrangement
volume, shape spatial arrangement and membrane organization of
Copyright © 2013 John Wiley & Sons, Ltd.microscopic to the macroscopic levels, the passive
transport of small drug-like molecules in the lung
was modeled based on differences in the physio-
logical, anatomical and histological organization
of airways and alveoli (Figure 3A). In this model,
the transmembrane transport was modeled using
the Fick and Goldman–Hodgkin–Katz equations
to describe the transport of small molecules across
the various membrane bound compartments
separating the lumen of the airway from theto build increasingly complex models from single cells to
to capture the transport into single cells and intracellular,
t across multicellular tissue layers. In essence, the mass of drug
e is calculated by multiplying the ﬂux of molecules across the
iffusing molecules, the ﬂux can be calculated based on the ion-
dients of freely soluble molecule species, and the membrane
e surface areas are biologically deﬁned, measurable parameters
and membrane organization of the cells, as well as the number,
organelles
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26 K.A. MIN ET AL.circulation. This model was used to predict the
rate of absorption of passively diffusing molecules
from the airway surface lining liquid, across the
epithelial cells, the interstitium, the capillary endo-
thelial cells and ultimately into the blood [123].
Furthermore, the predictions of the model were
tested after intravenous vs intratracheal injection
of ﬂuorescent compounds [124] (Figure 3B),
reﬂected in differences in the local distribution be-
havior and systemic absorption proﬁles of the ﬂuo-
rescent compounds with different physicochemical
properties in airways and alveoli (Figure 4). These
results illustrate how mechanistic cellular pharma-
cokinetic models can be used to analyse local
differences in the transport and distribution prop-
erties of small molecule chemical agents from the
individual organelles to a whole organ.Conclusions and Future Outlook
An important consideration to evaluate the scien-
tiﬁc value of a computational approach involves
assessing the predictive accuracy of the approach.
Comparing QSAR with differential equations-
based mechanistic modeling approaches [60] in
terms of predicting mitochondrial accumulation,
both methods have been found to predict the mi-
tochondrial localization of lipophilic cations and
lipophilic weak acids with some accuracy [60].
However, for electrically neutral species, includ-
ing zwitterions, predictions with the empirical
QSAR model were better than with the mechanis-
tic model [60]. For lipophilic cations of partially
ionized bases, the mechanistic model failed to
predict mitochondriotropic behavior in eight of
nine cases, while the QSAR model successfully
predicted all nine cases [60]. Thus, the QSAR
approach may be advantageous when there is a
good training set of molecules and a very speciﬁc
target organelle. In a different study, the predic-
tion performances of mechanistic and empirical
QSAR models were compared using a dataset of
toxicities against Tetrahymena pyriformis [125].
Based on this toxicity study, the mechanistic model
had a slightly higher predictive accuracy than the
empirical models (based on a leave-one-out cross-
validation and two types of leave-several-out
cross-validation approaches) [125]. More impor-
tantly, this second study suggests that theCopyright © 2013 John Wiley & Sons, Ltd.mechanism-based model performed better than
the empirical models for compounds falling out-
side the parameters space of the training set [125].
Nevertheless, as a tool to aid in experimental
design and data interpretation, differential equa-
tions-based cellular pharmacokinetic models can
be more useful than statistical QSAR models.
First, mechanistic predictive cellular pharmacoki-
netic models that are based on differential equa-
tions can be readily integrated with differential
equation-based systems biology models capturing
the interaction of biological components inside
cells. Using a mechanistic cellular pharmacoki-
netic model, concentrations of small molecule
drugs can be calculated inside cells, and these
concentrations can be incorporated into a systems
biology model to calculate the effect on a bio-
chemical reaction or signal transduction pathway.
Second, as we have argued before, mechanistic
models can be integrated across multiple scales
[126], to make predictions about differences in
drug transport and drug action at different sites
within the same organ. Lastly, from a biological
perspective, mechanistic pharmacokinetic models
can be integrated with systems biology models
and used to frame quantitative hypotheses about
the effects of exogenous, small molecule activators
or inhibitors on cell structure and function from
the local control of signal transduction pathways
[127] to the global control of cell population
dynamics [128–131]. Furthermore, the inability of
a mechanistic model to capture a molecule’s
behavior is often an indication of an unknown
mechanism affecting drug transport and distribu-
tion [132–136]. This can point to additional
experimental studies to identify new biological
phenomena affecting drug transport behavior
[66,137].
To conclude, a variety of computational ap-
proaches have been developed to analyse, inter-
pret and predict the transport and distribution
properties of small molecule chemical agents
inside cells. These approaches can be broadly
classiﬁed either as statistics-based QSAR or as
differential equations-based mechanistic models.
While statistics-based, predictive QSAR models
are simple and straightforward in terms of
pointing to chemical modiﬁcations that may be
useful for drug development purposes, mechanis-
tic models based on differential equations haveBiopharm. Drug Dispos. 35: 15–32 (2014)
DOI: 10.1002/bdd
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tems pharmacology. Mechanistic models that are
based on differential equations can be readily inte-
grated with other differential equation-based
models of drug–target interactions. Furthermore,
these integrated models can be subsequently
extended by adding the new mechanism, and
can be used to model compounds outside the
training dataset, and can be used as a starting
point for discovering new mechanisms. In line
with one of the primary objectives of systems
pharmacology, which is to predict the effects of
exogenous chemical agents on living systems,
many mechanistic cell-based pharmacokinetic
models are already being used to help analyze
and predict the transport, distribution, metabo-
lism and excretion properties of exogenous chem-
ical agents from the subcellular to the organism
levels. Therefore, further integration of differential
equations-based cellular pharmacokinetics with
mechanistic systems biology modeling research
seems like a natural next step in the advancement
of systems pharmacology.Acknowledgements
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